AKT1 and prostate carcinoma: And p-PRAS40-Thr246, a highly specific and stable effector molecule downstream of PI3K/AKT signaling pathway, can predict the sensitivity of prostate cancer cells and triple-negative breast cancer cells to AKT inhibitors, and also affect the prognosis of gastric cancer (9, 10).